Tauriga Sciences, Inc. Begins Initial Production Run of CBG-Infused Tauri-Gum
CBG gum set to hit the market in March 2020.
Tauriga Sciences, Inc. has begun production of its proprietary cannabigerol (CBG) isolate-infused version of Tauri-Gum.
Each blister pack of CBG Tauri-Gum will contain eight tablets, featuring 10mg of CBG per tablet. The gum will come in a Peach-Lemon flavor, instead of Starfruit-Peach, as originally contemplated.
Set to hit the market in March, the product will be kosher-certified, vegan, Non-GMO, gluten-free and allergen-free. The suggested retail price has been set at $19.99 per blister pack or $199.99 per retail box.
Over the past two months, Tauriga Sciences has experienced strong levels of interest in this CBG-infused version of Tauri-Gum. The company believes this product has the potential to enhance the value of its Tauri-Gum brand and drive revenue growth.
CBG is a non-psychoactive cannabinoid that plays an important role in the biochemistry of the cannabis plant. CBG acts as a chemical precursor to other cannabinoids such as THC and CBD. This conversion typically takes place six to eight weeks in the flowering cycle. CBG is present only in trace amounts in most cannabis strains. However, some hemp strains are specifically cultivated to generate higher yields of this cannabinoid.
CBG holds promise to be a key constituent in the overall medicinal benefits cannabis may provide. As cannabis research continues to evolve, CBG may emerge as one of the most therapeutically applicable and diverse cannabinoids to offer a wide range of possible remedies.
CBG is not scheduled by the UN Convention on Psychotropic Substances. In the United States, it is not a controlled substance under the Controlled Substances Act as long as it is not produced from the controlled parts of the cannabis plant.